Thomas C Whisenant

Dr. Thomas C Whisenant

University of California, San Diego, San Diego, California, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in BioTechniques
Verified
Journal Article
Open access
SHSteven Head
Steven Head
HKH. Kiyomi Komori
H. Kiyomi Komori
SLSarah LaMere
Sarah LaMere
TWThomas C Whisenant
Thomas C Whisenant
FNFilip Van Nieuwerburgh
Filip Van Nieuwerburgh
POPhillip Ordoukhanian
Phillip Ordoukhanian
High-throughput sequencing, also known as next-generation sequencing (NGS), has revolutionized genomic research. In recent years, NGS technology has steadily improved, with costs dropping and the n...

12 August 2004 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SFStuart M. Flechner
Stuart M. Flechner
SKSunil Kurian
Sunil Kurian
SHSteven R. Head
Steven R. Head
SSStarlette M. Sharp
Starlette M. Sharp
TWThomas C Whisenant
Thomas C Whisenant
DSDaniel R. Salomon
Daniel R. Salomon
A major challenge for kidney transplantation is balancing the need for immunosuppression to prevent rejection, while minimizing drug-induced toxicities. We used DNA microarrays (HG-U95Av2 GeneChips, Affymetrix) to determine gene expression profiles for kidney biopsies and peripheral blood lymphocytes (PBLs) in transplant patients including normal donor kidneys, well-functioning transplants without rejection, kidneys undergoing acute rejection, and transplants with renal dysfunction without rejection. We developed a data analysis schema based on expression signal determination, class comparison and prediction, hierarchical clustering, statistical power analysis and real-time quantitative PCR validation. We identified distinct gene expression signatures for both biopsies and PBLs that correlated significantly with each of the different classes of transplant patients. This is the most complete report to date using commercial arrays to identify unique expression signatures in transplant biopsies distinguishing acute rejection, acute dysfunction without rejection and well-functioning transplants with no rejection history. We demonstrate for the first time the successful application of high density DNA chip analysis of PBL as a diagnostic tool for transplantation. The significance of these results, if validated in a multicenter prospective trial, would be the establishment of a metric based on gene expression signatures for monitoring the immune status and immunosuppression of transplanted patients.

1 November 2004 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SFStuart M. Flechner
Stuart M. Flechner
SKSunil Kurian
Sunil Kurian
KSKim Solez
Kim Solez
DCDaniel J. Cook
Daniel J. Cook
JBJames T. Burke
James T. Burke
DSDaniel R. Salomon
Daniel R. Salomon
We performed a randomized prospective trial comparing calcineurin inhibitor (CNI)-free to CNI-based immunosuppression to determine the impact on renal function, structure and gene expression. Sixty-one kidney recipients treated with basiliximab mycophenolate mofetil (MMF) and prednisone (P) were randomly assigned to concentration-controlled sirolimus or cyclosporine. Two years post-transplant 55 patients underwent renal function studies, 48 (87%) underwent transplant biopsies; all classified by Banff scoring and 41 by DNA microarrays. Comparing sirolimus/MMF/P to cyclosporine/MMF/P there was a significantly lower serum creatinine (1.35 vs. 1.81 mg/dL; p = 0.008), higher Cockroft-Gault glomerular filtration rate (GFR) (80.4 vs. 63.4 mL/min; p = 0.008), iothalamate GFR (60.6 vs. 49.2 mL/min; p = 0.018) and Banff 0 (normal) biopsies (66.6 vs. 20.8%; p = 0.013). Regression analysis of calculated GFRs from 1 to 36 months yielded a positive slope for sirolimus of 3.36 mL/min/year, and a negative slope for cyclosporine of -1.58 mL/min/year (p = 0.008). Gene expression profiles from kidneys with higher Banff chronic allograft nephropathy (CAN) scores confirmed significant up-regulation of genes responsible for immune/inflammation and fibrosis/tissue remodeling. At 2 years the sirolimus-treated recipients have better renal function, a diminished prevalence of CAN and down-regulated expression of genes responsible for progression of CAN. All may provide for an alternative natural history with improved graft survival.

9 July 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JFJohn J. Friedewald
John J. Friedewald
SKSunil Kurian
Sunil Kurian
RHRaymond L. Heilman
Raymond L. Heilman
TWThomas C Whisenant
Thomas C Whisenant
EPEmilio D. Poggio
Emilio D. Poggio
MAMichael M. Abecassis
Michael M. Abecassis
Non‐invasive biomarkers are needed to monitor stable patients following kidney transplantation (KT), as sub‐clinical acute rejection (subAR), currently detectable only with surveillance biopsies can lead to chronic rejection and graft loss. We conducted a multi‐center study to develop a blood‐based molecular biomarker for subAR using peripheral blood paired with surveillance biopsies and strict clinical phenotyping algorithms for discovery and validation. At a predefined threshold, 72‐75% of KT recipients achieved a negative biomarker test correlating with the absence of subAR (NPV: 78‐88%), while a positive test was obtained in 25‐28% correlating with the presence of subAR (PPV: 47‐61%). The clinical phenotype and biomarker independently and statistically correlated with a composite clinical endpoint (renal function, biopsy‐proven acute rejection, >grade 2 interstitial fibrosis and tubular atrophy), as well as with de novo donor‐specific antibodies. We also found that <50% showed histological improvement of subAR on follow up biopsies despite treatment, and that the biomarker could predict this outcome. Our data suggest that a blood‐based biomarker that reduces the need for the indiscriminate use of invasive surveillance biopsies, and that correlates with transplant outcomes could be used to monitor KT recipients with stable renal function, including after treatment for subAR, potentially improving KT outcomes.

19 October 2005 in Glycobiology
Verified
Journal Article
Open access
PDF file
ECElena M Comelli
Elena M Comelli
SHSteven R. Head
Steven R. Head
TGTim Gilmartin
Tim Gilmartin
TWThomas C Whisenant
Thomas C Whisenant
SHStuart M. Haslam
Stuart M. Haslam
JPJames C. Paulson
James C. Paulson
Glycosylation is the most common posttranslational modification of proteins, yet genes relevant to the synthesis of glycan structures and function are incompletely represented and poorly annotated on the commercially available arrays. To fill the need for expression analysis of such genes, we employed the Affymetrix technology to develop a focused and highly annotated glycogene-chip representing human and murine glycogenes, including glycosyltransferases, nucleotide sugar transporters, glycosidases, proteoglycans, and glycan-binding proteins. In this report, the array has been used to generate glycogene-expression profiles of nine murine tissues. Global analysis with a hierarchical clustering algorithm reveals that expression profiles in immune tissues (thymus [THY], spleen [SPL], lymph node, and bone marrow [BM]) are more closely related, relative to those of nonimmune tissues (kidney [KID], liver [LIV], brain [BRN], and testes [TES]). Of the biosynthetic enzymes, those responsible for synthesis of the core regions of N- and O-linked oligosaccharides are ubiquitously expressed, whereas glycosyltransferases that elaborate terminal structures are expressed in a highly tissue-specific manner, accounting for tissue and ultimately cell-type-specific glycosylation. Comparison of gene expression profiles with matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) profiling of N-linked oligosaccharides suggested that the α1-3 fucosyltransferase 9, Fut9, is the enzyme responsible for terminal fucosylation in KID and BRN, a finding validated by analysis of Fut9 knockout mice. Two families of glycan-binding proteins, C-type lectins and Siglecs, are predominately expressed in the immune tissues, consistent with their emerging functions in both innate and acquired immunity. The glycogene chip reported in this study is available to the scientific community through the Consortium for Functional Glycomics (CFG) (http://www.functionalglycomics.org).

15 August 2006 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ECElena M Comelli
Elena M Comelli
MSMark Sutton-Smith
Mark Sutton-Smith
QYQi Yan
Qi Yan
MAMargarida Amado
Margarida Amado
MPMaria Panico
Maria Panico
JPJames C. Paulson
James C. Paulson
Differentiation and activation of lymphocytes are documented to result in changes in glycosylation associated with biologically important consequences. In this report, we have systematically examined global changes in N-linked glycosylation following activation of murine CD4 T cells, CD8 T cells, and B cells by MALDI-TOF mass spectrometry profiling, and investigated the molecular basis for those changes by assessing alterations in the expression of glycan transferase genes. Surprisingly, the major change observed in activated CD4 and CD8 T cells was a dramatic reduction of sialylated biantennary N-glycans carrying the terminal NeuGcα2-6Gal sequence, and a corresponding increase in glycans carrying the Galα1-3Gal sequence. This change was accounted for by a decrease in the expression of the sialyltransferase ST6Gal I, and an increase in the expression of the galactosyltransferase, α1-3GalT. Conversely, in B cells no change in terminal sialylation of N-linked glycans was evident, and the expression of the same two glycosyltransferases was increased and decreased, respectively. The results have implications for differential recognition of activated and unactivated T cells by dendritic cells and B cells expressing glycan-binding proteins that recognize terminal sequences of N-linked glycans.